Patents by Inventor Stefan Stevanovic

Stefan Stevanovic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tumour-associated peptides binding to MHC-molecules
    Publication number: 20090221509
    Abstract: The invention relates to a tumour-associated peptide with an amino acid sequence that is selected from the group consisting of SEQ ID-No. 1 to SEQ ID-No. 101 of the attached sequence protocol, wherein the peptide has the ability to bind to a molecule of the human major-histocompatibility-complex (MHC) class-I. In addition, the invention relates to the use of the peptides and the nucleic acids encoding for the peptides for the production of a medicament, and for the treatment of tumorous diseases and/or adenomatous diseases. Furthermore, a pharmaceutical composition is described that has at least one of the peptides.
    Type: Application
    Filed: March 23, 2004
    Publication date: September 3, 2009
    Inventors: Hans Georg Rammensee, Stefan Stevanovic, Toni Weinschenk, Claudia Lemmel, Jörg Dengjel, Oliver Schoor
  • Peptide for triggering an immune reaction against tumor cells
    Patent number: 7528224
    Abstract: The invention relates to a peptide for triggering an immune response to tumor cells. Said peptide has an optionally modified fragment of the protein that is encoded by the gene MUC-1. Said protein triggers an HLA-A2-restricted immune response.
    Type: Grant
    Filed: May 1, 2006
    Date of Patent: May 5, 2009
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Peter Brossart, Stefan Stevanovic, Wolfram Brugger, Lothar Kanz, Hans Georg Rammensee
  • Ny-Eso-1 Peptides Which Bind To Class II Molecules And Uses Thereof
    Publication number: 20080187548
    Abstract: The invention relates to peptides which consist of amino acid sequences found in the NY-ESO-1 molecule, which bind to MHC-Class II molecules. These can be used alone, or in combination with other peptides.
    Type: Application
    Filed: March 1, 2004
    Publication date: August 7, 2008
    Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH
    Inventors: Michael Pfreudschuh, Frank Neumann, Hans-George Rammensee, Stefan Stevanovic
  • Tumor-associated peptides binding to MHC-molecules
    Patent number: 7396904
    Abstract: The invention relates to a tumor-associated peptide containing an amino sequence, which is selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:79 of the enclosed listing. The peptide has the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I. The invention also relates to the use of the peptides for manufacture of a medicament and for treating tumorous diseases. The invention further relates to a pharmaceutical composition, which comprises at least one of the peptides.
    Type: Grant
    Filed: November 29, 2004
    Date of Patent: July 8, 2008
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Toni Weinschenk, Hans Georg Rammensee, Stefan Stevanovic
  • TUMOUR-ASSOCIATED PEPTIDES BINDING TO MHC-MOLECULES
    Publication number: 20080057077
    Abstract: The invention relates to a tumor-associated peptide containing an amino sequence, which is selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:79 of the enclosed listing. The peptide has the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I. The invention also relates to the use of the peptides for manufacture of a medicament and for treating tumorous diseases. The invention further relates to a pharmaceutical composition, which comprises at least one of the peptides.
    Type: Application
    Filed: August 30, 2007
    Publication date: March 6, 2008
    Applicant: Immatics Biotechnologies GmbH
    Inventors: Toni Weinschenk, Hans Rammensee, Stefan Stevanovic
  • TUMOUR-ASSOCIATED PEPTIDES BINDING TO MHC-MOLECULES
    Publication number: 20080051347
    Abstract: The invention relates to a tumor-associated peptide containing an amino sequence, which is selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:79 of the enclosed listing. The peptide has the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I. The invention also relates to the use of the peptides for manufacture of a medicament and for treating tumorous diseases. The invention further relates to a pharmaceutical composition, which comprises at least one of the peptides.
    Type: Application
    Filed: August 30, 2007
    Publication date: February 28, 2008
    Applicant: Immatics Biotechnologies GmbH
    Inventors: Toni Weinschenk, Hans Rammensee, Stefan Stevanovic
  • Isolated nucleic acid molecules encoding isolated peptides which correspond to contiguous amino acids of an SSX molecule or NY-ESO-1 and uses thereof
    Patent number: 7270819
    Abstract: The invention relates to members of the SSX family of genes, as well as their uses. Also a part of the invention are peptides derived from SSX molecules and the NY-ESO-1 molecule, which form complexes with HLA molecules, leading to lysis of cells presenting these complexes, by cytolytic T cells.
    Type: Grant
    Filed: June 21, 2002
    Date of Patent: September 18, 2007
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Ozlem Tureci, Ugur Sahin, Michael Pfreundschuh, Hans Georg Rammensee, Stefan Stevanovic
  • Peptide for triggering an immune reaction against tumor cells
    Patent number: 7087712
    Abstract: The invention relates to a peptide for triggering an immune response to tumor cells. Said peptide has an optionally modified fragment of the protein that is encoded by the gene MUC-1. Said protein triggers an HLA-A2-restricted immune response.
    Type: Grant
    Filed: March 28, 2000
    Date of Patent: August 8, 2006
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Peter Brossart, Stefan Stevanovic, Wolfram Brugger, Lothar Kanz, Hans-Georg Rammensee
  • Tumor-associated peptides binding to MHC-molecules
    Publication number: 20050222390
    Abstract: The invention relates to a tumor-associated peptide containing an amino sequence, which is selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:79 of the enclosed listing. The peptide has the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I. The invention also relates to the use of the peptides for manufacture of a medicament and for treating tumorous diseases. The invention further relates to a pharmaceutical composition, which comprises at least one of the peptides.
    Type: Application
    Filed: November 29, 2004
    Publication date: October 6, 2005
    Inventors: Toni Weinschenk, Hans Rammensee, Stefan Stevanovic
  • Isolated nucleic acid molecules encoding isolated peptides which correspond to contiguous amino acids of an SSX molecule or NY-ESO-1 and uses thereof
    Publication number: 20030185844
    Abstract: The invention relates to members of the SSX family of genes, as well as their uses. Also a part of the invention are peptides derived from SSX molecules and the NY-ESO-1 molecule, which form complexes with HLA molecules, leading to lysis of cells presenting these complexes, by cytolytic T cells.
    Type: Application
    Filed: June 21, 2002
    Publication date: October 2, 2003
    Inventors: Ozlem Tureci, Ugur Sahin, Michael Pfreundschuh, Hans Georg Rammensee, Stefan Stevanovic
  • Isolated peptides consisting of amino acid sequences found in SSX or NY-ESO-1 molecules, which bind to HLA molecules
    Patent number: 6548064
    Abstract: The invention relates to members of the SSX family of genes, as well as their uses. Also a part of the invention are peptides derived from SSX molecules and the NY-ESO-1 molecule, which form complexes with HLA molecules, leading to lysis of cells presenting these complexes, by cytolytic T cells.
    Type: Grant
    Filed: June 25, 1999
    Date of Patent: April 15, 2003
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Ozlem Tureci, Ugur Sahin, Michael Pfreundschuh, Hans Georg Rammensee, Stefan Stevanovic
  • Determination of peptide motifs on MHC molecules
    Patent number: 5747269
    Abstract: The present invention concerns a method for the determination of allele-specific peptide motifs on molecules of the major histocompatibility complex (MHC) of classes I and II as well as the peptide motifs which are obtainable by the method according to the invention. In addition the use of the peptide motifs according to the invention for the production of a diagnostic or therapeutic agent is disclosed.
    Type: Grant
    Filed: May 9, 1994
    Date of Patent: May 5, 1998
    Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.
    Inventors: Hans-Georg Rammensee, Kirsten Falk, Olaf Rotzschke, Stefan Stevanovic, Gunther Jung